Catalyst Wire Dossier Catalyst Wire Dossier

Lasmiditan

Lasmiditan · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

29 regulatory and trial events tracked for Lasmiditan, covering 2018-07-30 to 2026-06-25. Get the full timeline:

Most recent: Clinical Trial Results: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine [Phase 3]

See pricing